|Bid||250.11 x 800|
|Ask||265.54 x 900|
|Day's Range||250.00 - 258.67|
|52 Week Range||232.01 - 317.17|
|Beta (5Y Monthly)||1.04|
|PE Ratio (TTM)||9.15|
|Forward Dividend & Yield||2.88 (1.18%)|
|Ex-Dividend Date||May 18, 2022|
|1y Target Est||N/A|
“Without Labcorp, Burlington would be really, really struggling," David King, former CEO of the Triad-based global life sciences giant, said.
LabCorp's (LH) new assay is claimed to have shown a demonstrable clinical advantage in patients suffering from melanoma.
David King, who led Labcorp from a tumultuous time to becoming a Triangle juggernaut, was honored in a lively event as life science leaders packed a ballroom to listen to an industry icon.